PR Newswire
ANDOVER, Mass., May 8, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2025.
Recent Highlights
Total revenue of $143.5 million in the first quarter of 2025, a 48% increase compared to the first quarter of 2024Generated net income of $25.7 million or $0.70 per fully diluted share in the first quarter of 2025Raising full year 2025 revenue guidance to $565 million to $585 millionOwned 21 aircraft as of March 31, 2025Announced strategic plan to open design center of excellence and new disposables manufacturing facility in Mirandola, ItalyHosted annual symposium at the International Society of Heart and Lung Transplantation (ISHLT) 45th Annual Meeting & Scientific Session in Boston; highlighted latest design and potential sample size of upcoming next-gen clinical programs10 abstracts and presentations at ISHLT featured OCS™ & NOP™ clinical value
ANDOVER, Mass., April 24, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.
NEW YORK, April 14, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
SAN DIEGO, April 14, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of TransMedics Group, Inc. (NASDAQ: TMDX) publicly traded securities between February 28, 2023 and January 10, 2025, inclusive (the "Class Period"), have until this upcoming Tuesday, April 15, 2025 to seek appointment as lead plaintiff of the TransMedics class action lawsuit. Captioned Jewik v. TransMedics Group, Inc., No. 25-cv-10385 (D. Mass.), the TransMedics class action lawsuit charges TransMedics and of TransMedics' executives with violations of the Securities Exchange Act of 1934.
LOS ANGELES, April 13, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ: TMDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, April 13, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of TransMedics Group, Inc. (NASDAQ: TMDX) between February 28, 2023 and January 10, 2025, both dates inclusive (the "Class Period"), of the important April 15, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.
So what: If you purchased TransMedics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
PHILADELPHIA, April 12, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX) on behalf of purchasers of TransMedics securities between February 28, 2023 through January 10, 2025, inclusive (the "Class Period").
Investor Deadline: Investors who purchased or acquired TRANSMEDICS securities during the Class Period may, no later than APRIL 15, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.
NEW YORK, April 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of TransMedics investors who were adversely affected by alleged securities fraud between February 28, 2023 and January 10, 2025. Follow the link below to get more information and be contacted by a member of our team:
RADNOR, Pa., April 10, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against TransMedics Group, Inc. ("TransMedics") (NASDAQ: TMDX) on behalf of those who purchased or otherwise acquired TransMedics securities between February 28, 2023, and January 10, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is April 15, 2025.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In TransMedics To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in TransMedics between February 23, 2023 and January 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, April 10, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX) and reminds investors of the April 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
NEW YORK, April 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of TransMedics Group, Inc. (NASDAQ: TMDX).
Shareholders who purchased shares of TMDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
NEW YORK, April 8, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of TransMedics Group, Inc. (NASDAQ: TMDX) between February 28, 2023 and January 10, 2025, both dates inclusive (the "Class Period"), of the important April 15, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.
So what: If you purchased TransMedics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
SAN DIEGO, April 8, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of TransMedics Group, Inc. (NASDAQ: TMDX) publicly traded securities between February 28, 2023 and January 10, 2025, both dates inclusive (the "Class Period"), have until Tuesday, April 15, 2025 to seek appointment as lead plaintiff of the TransMedics class action lawsuit. Captioned Jewik v. TransMedics Group, Inc., No. 25-cv-10385 (D. Mass.), the TransMedics class action lawsuit charges TransMedics and of TransMedics' executives with violations of the Securities Exchange Act of 1934.
PHILADELPHIA, April 8, 2025 /PRNewswire/ -- A securities class action lawsuit has been filed against Transmedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX). The lawsuit has been filed on behalf of purchasers of TransMedics securities between February 28, 2023 and January 10, 2025, inclusive (the "Class Period").
CLICK HERE TO LEARN MORE ABOUT THIS LAWSUIT.
Investors who purchased or acquired Transmedics Group, Inc. securities during the Class Period may, no later than APRIL 15, 2025, seek to be appointed as a lead plaintiff representative of the class.
NEW YORK, April 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
NEW YORK, April 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of TransMedics investors who were adversely affected by alleged securities fraud between February 28, 2023 and January 10, 2025. Follow the link below to get more information and be contacted by a member of our team:
LOS ANGELES, April 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ: TMDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, April 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of TransMedics Group, Inc. (NASDAQ: TMDX).
Shareholders who purchased shares of TMDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
NEW YORK, April 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of TransMedics investors who were adversely affected by alleged securities fraud between February 28, 2023 and January 10, 2025. Follow the link below to get more information and be contacted by a member of our team:
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In TransMedics To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $50,000 in TransMedics between February 23, 2023 and January 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, April 3, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX) and reminds investors of the April 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.
RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.
Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.
On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.